Dr Rupalla brings to 4D pharma over twenty years of experience in the pharmaceutical industry, extensive regulatory and clinical expertise in the fields of oncology and neuroscience. Dr Rupalla has previously served in senior positions at
Dr Rupalla will make a considerable impact on 4D pharma's immediate and long-term clinical strategy across its Live Biotherapeutic development pipeline, including the application of the Rx platform and our earlier pre-clinical assets, but also our lead immuno-oncology candidate MRx0518 and neurodegenerative disease programs MRx0029 and MRx0005. Following the recent successful completion of the Part A safety phase of its ongoing trial of MRx0518 in combination with immune checkpoint inhibitor (ICI) Keytruda(R), which achieved a disease control rate (DCR) of 42 percent in heavily pre-treated patients refractory to prior ICI therapy, the Part B cohort expansion phase of the trial is currently enrolling at multiple sites as announced. Dr Rupalla will be a valuable new voice helping to guide and deliver the expanding global clinical development program for MRx0518.
Dr Rupalla currently serves as Senior Vice President, Global Head Regulatory Affairs, Medical Documentation and R&D Quality at Lundbeck, a leading biopharmaceutical developing novel therapeutics for diseases of the central nervous system (CNS).
Dr Rupalla has a Ph.D in CNS Pharmacology from the Philipps-University Marburg,
4D pharma also announces the retirement of
Additional Disclosures
The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. Katrin Juliane Rupalla, aged 53 years, has been a director of the following companies during the five years preceding the date of this announcement:
Current directorships/partnerships: iQure
Past directorships/partnerships: N/A
Katrin Rupalla does not currently hold any ordinary shares in the Company.
Save as set out above there are no further disclosures pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies in respect of the appointment of Katrin Rupalla.
About 4D
Founded in
4D's Live Biotherapeutic Products are orally delivered single strains of bacteria that are naturally found in the healthy human gut. The Company has six clinical studies in progress, namely a Phase II clinical study of BLAUTIX® in Irritable Bowel Syndrome (IBS), a Phase I/II study of MRx0518 in combination with KEYTRUDA® (pembrolizumab) in solid tumours, a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumours, a Phase I study of MRx0518 in patients with pancreatic cancer, a Phase I/II study of MRx-4DP0004 in asthma, and a Phase II study of MRx-4DP0004 in patients hospitalised with COVID-19. Preclinical-stage programs include candidates for CNS disease such as Parkinson's disease and other neurodegenerative conditions. The Company has a research collaboration with MSD, a tradename of
For more information, refer to https://www.4dpharmaplc.com.
.
(C) 2020 M2 COMMUNICATIONS, source